There is more to soft tissue sarcomas than just grade and size

Lay Summary Sarculator is better at predicting patients with sarcoma at the highest risk of death than current staging systems and should be used to determine appropriate patients for future studies. Sarculator is better at assessing the risk of sarcoma metastases or death than American Joint Committee on Cancer staging. Sarculator‐calculated 10‐year survival < 60% should be included as an entry criterion in future adjuvant/neoadjuvant studies.